SCHEMBL1853397

SCHEMBL1853397

COc1ccc2oc(C(N)=O)c(NC(=O)[C@H]3CC(F)(F)CN3C(=O)OC(C)(C)C)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.40
KDM4E B2RXH2 8/20 0.40
HSD17B10 Q99714 5/20 0.40
HPGD P15428 5/20 0.40
TSHR P16473 5/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
NPSR1 Q6W5P4 2/20 0.40
MAPK10 P53779 1/20 0.40
SMN1; SMN2 Q16637 5/20 0.38
HTT P42858 3/20 0.38
TP53 P04637 2/20 0.38
MAPT P10636 4/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
LMNA P02545 1/20 0.38
DHODH Q02127 1/20 0.38
ALOX15 P16050 1/20 0.37
USP2 O75604 1/20 0.37
RAD52 P43351 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1853394 1.00 ALDH1A1 (0.40) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL1851485 0.89 KDM4E (0.50) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL1850430 0.89 KMT2A (0.42) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL1850429 0.89 KMT2A (0.42) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL1851482 0.89 KDM4E (0.50) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL4279864 0.86 KDM4E (0.43) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL1851790 0.84 CFD (0.43) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL1851107 0.84 CFD (0.43) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL1851792 0.84 CFD (0.43) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL1855333 0.84 NPSR1 (0.49) ALDH1A1KDM4EHSD17B10HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
EP-2097419-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS Exelixis, Inc. (US) 2009-09-09 EP disclosed
WO-2009086264-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS, INC. (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247559-A1 Benzofuropyrimidinones F12, BRI3BP, BRD1 ALDH1A1 315/4885KDM4E 1855/4885HSD17B10 1290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.